A Phase II study to evaluate the efficacy of erlotinib in advanced NSCLC patients who have wild-type EGFR and EGFR gene amplification

Autor:	Shunichi Tamori, Taro Yoneda, Hirokazu Touge, Takashi Sone, Satoshi Nomura, Hiroki Shirasaki, Ryo Matsunuma, Koji Kurokawa, Masaru Nishitsuji, Josuke Hara, Hayato Koba, Tomoyuki Araya, Yuichi Tambo, Shingo Nishikawa, Hideharu Kimura, Yoshihisa Ishiura, Toshiyuki Kita, Kazuhiko Shibata, Tamami Sakai, Kazuo Kasahara
Rok vydání:	2015
Předmět:	Cancer Research business.industry Wild type Phases of clinical research medicine.disease respiratory tract diseases Oncology Egfr mutation Cancer research Medicine EGFR Gene Amplification Erlotinib Previously treated business Lung cancer neoplasms medicine.drug
Zdroj:	Journal of Clinical Oncology. 33:e19028-e19028
ISSN:	1527-7755 0732-183X
DOI:	10.1200/jco.2015.33.15_suppl.e19028
Popis:	e19028 Background: Erlotinib is one of the standard therapies for previously treated patients (pts) of advanced non-small-cell lung cancer (NSCLC) without EGFR mutations. However, response rate of ...
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_________::a16ca9f57facf6d3d7d3013de4a59d0d https://doi.org/10.1200/jco.2015.33.15_suppl.e19028 Zobrazit plný text záznamu